

552,401

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 October 2004 (21.10.2004)

PCT

(10) International Publication Number  
**WO 2004/089987 A1**

(51) International Patent Classification<sup>7</sup>: **C07K 14/81**,  
G01N 33/68, C07K 16/38, A61K 38/17

(21) International Application Number:  
PCT/EP2004/003746

(22) International Filing Date: 7 April 2004 (07.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/461,560 8 April 2003 (08.04.2003) US

(71) Applicant (for all designated States except US): **GENOVA LTD.**; Canon's Court, 22 Victoria Street, Hamilton HM 12 (BM).

(71) Applicant (for AT only): **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ARGOUD-PUY, Guilaine** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **BEDERR, Nassima** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin

(CH). **BOUGUELERET, Lydie** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **CUSIN, Isabelle** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **MAHE, Eve** [FR/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **NIKNEJAD, Anne** [CH/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH). **REFFAS, Samia** [CH/CH]; GeneProt, Inc., 2, pre-de-la-Fontaine, CH-1217 Meyrin (CH).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: SECRETED POLYPEPTIDE SPECIES ASSOCIATED WITH CARDIOVASCULAR DISORDERS

**SEQ ID NO:1**

1 MKSSGLPPFL WLLALGTLAP WAVEGSGKSF KAGVCPPKKS AQCLRYKKPE CQSDWQCPGK  
61 KRCCPDTCGI KCLDPVDTPN PTRRKPGKCP VTYGQCLMLN PPNFCEMDGQ CKRDLKCCMG  
121 MCGKSCVSPV KA

**SEQ ID NO:2**

1 SGKSFKAGVC PPKKSAQCLR YKKPECQSDW QCPGKKRCCP DTCGIKKCLDP VDTNPNTRRK  
61 PGKCPVTYGQ CLMLNPPNFC EMDGQCKRDL KCCMGKCGKS CVSPVKA

**SEQ ID NO:3**

YKKPECQSDW QCPGK

**SEQ ID NO:4**

KCLDPVDTPN TR

(57) Abstract: The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and treatment of cardiovascular disorders.

WO 2004/089987 A1



Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*